A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Abstract This single-arm, multi-center clinical trial aimed to evaluate the safety, tolerability, DLT, recommended dose (RD), preliminary efficacy, and pharmacokinetics (PK) characteristics of lurbinectedin, a selective inhibitor of oncogenic transcription, in Chinese patients with advanced solid tu...

Full description

Bibliographic Details
Main Authors:	Ying Cheng, Chunjiao Wu, Lin Wu, Jun Zhao, Yanqiu Zhao, Lulu Chen, Ying Xin, Liang Zhang, Pinhua Pan, Xingya Li, Juan Li, Xiaorong Dong, Ke Tang, Emei Gao, Fei Yu
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-54223-5

Similar Items

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
by: Salvador Fudio, et al.
Published: (2023-06-01)

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
by: Shetal Patel, et al.
Published: (2021-05-01)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
by: Raj Hanvesakul, et al.
Published: (2023-04-01)

Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea
by: Shim JS, et al.
Published: (2024-10-01)

Lurbinectedin in small cell lung cancer
by: Anna Manzo, et al.
Published: (2022-08-01)

Second‐line lurbinectedin as a new treatment option for small‐cell lung cancer: Preliminary results in real‐clinical practice
by: Anne‐Claire Toublanc, et al.
Published: (2022-08-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
by: Rebekah Rittberg, et al.
Published: (2022-12-01)

The second terminations of the suboccipital muscles: An assistant pivot for the To Be Named Ligament.
by: Xiao-Ying Yuan, et al.
Published: (2017-01-01)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
by: Christopher W Schultz, et al.
Published: (2023-07-01)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
by: Louis Gros, et al.
Published: (2021-06-01)

Efficacy and toxicity of lurbinectedin in subsequent systemic therapy of extensive-stage small cell lung cancer: a meta-analysis
by: Jiayi Tang, et al.
Published: (2024-11-01)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
by: Tej Tummala, et al.
Published: (2023-10-01)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
by: Adrián Povo-Retana, et al.
Published: (2023-08-01)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion
by: Filippo Simona, et al.
Published: (2022-12-01)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
by: Lucia Musacchio, et al.
Published: (2022-02-01)

Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer
by: Christopher W Schultz, et al.
Published: (2024-02-01)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
by: Kauffmann-Guerrero D, et al.
Published: (2020-03-01)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
by: Federico Costanzo, et al.
Published: (2022-03-01)

High mRNA expression of POU2F3 in small cell lung cancer cell lines predicts the effect of lurbinectedin
by: Shinji Matsui, et al.
Published: (2022-04-01)

Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug–Drug Interaction Study
by: Irene Moreno, et al.
Published: (2024-04-01)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
by: Oliver Kepp, et al.
Published: (2020-01-01)

Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment—Progresses in Their Use in Combined Cancer Therapy
by: Adrián Povo-Retana, et al.
Published: (2024-01-01)

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
by: Andres Poveda, et al.
Published: (2021-02-01)

Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy
by: Mohammad Jad Moussa, et al.
Published: (2024-06-01)

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC-MS/MS.
by: Nicholas King, et al.
Published: (2023-01-01)

Quantitative determination of lurbinectedin, its unbound fraction and its metabolites in human plasma utilizing ultra-performance LC–MS/MS
by: Nicholas King, et al.
Published: (2023-01-01)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
by: Alberto Zambelli, et al.
Published: (2023-01-01)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
by: Angiolo Gadducci, et al.
Published: (2022-11-01)

Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models
by: María Virtudes Céspedes, et al.
Published: (2016-12-01)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
by: Ryoko Takahashi, et al.
Published: (2016-01-01)

The pivotal role of timing of intravenous thrombolysis bridging treatment prior to endovascular thrombectomy
by: Jeremy Molad, et al.
Published: (2023-12-01)

MicroRNA-31: a pivotal oncogenic factor in oral squamous cell carcinoma
by: Xiaojiao Lin, et al.
Published: (2022-03-01)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
by: Ying Zhao, et al.
Published: (2022-09-01)

Review of outcomes in a veteran treated with lurbinectedin long-term for extensive-stage small cell lung cancer: A case report
by: Jana Sawyer, et al.
Published: (2025-03-01)

Control the Epithelial Barrier: A Pivotal First Line of Defense
by: Catherine M McKay, et al.
Published: (2004-01-01)

Excel 2007 PivotTables and PivotCharts /
by: 178516 Aitken, Peter G.
Published: (2007)

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
by: Shujing Shen, et al.
Published: (2024-07-01)

Sparsity Prevention Pivoting Method for Linear Programming
by: Peiqiang Li, et al.
Published: (2018-01-01)

Gyroscope Pivot Bearing Dimension and Surface Defect Detection
by: Xudong Li, et al.
Published: (2011-03-01)